Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
Germany has received nearly 900 applications for cannabis cultivation associations, but only just over half…
A Senate stopgap funding bill would delay the federal prohibition on most hemp-derived THC products…
He smokes in boardrooms, but he’s still on that underground frequency. This content originally appeared…
Fox News opinion ran a piece recently from Scott Chipman, vice president of Americans Against…
For our 50th anniversary, we handed the plant to the artists making its most striking…
Corporate valuation increased in 21 of the 38 states studied following medical marijuana legalization. Gross…